Jasper for Autism Spectrum Disorders

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Autism Spectrum Disorders+2 More
Jasper - Behavioral
Eligibility
< 18
All Sexes
What conditions do you have?
Select

Study Summary

The aim of the study is to determine whether a targeted behavioral intervention can lead to both changes in early communication skills and in neural responses in toddlers and preschoolers with autism.

Eligible Conditions
  • Autism Spectrum Disorders
  • Autism Spectrum Disorder

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Autism Spectrum Disorders

Study Objectives

9 Primary · 0 Secondary · Reporting Duration: Assessment occurs at week 1, week 6, and week 12, with an intervention in weeks 2-11

Week 12
Change in EEG Frequency Data- Grasping Objects
Change in EEG Frequency Data- Observing actions
Change in EEG Frequency Data- Resting State
Change in imitation measured with the Elicited Imitation Battery (adapted from Rogers et al., 2003)
Change in joint attention measured with the Early Social and Communication scales (ESCS)
Change in language measured with the Elicitation of Language Sample Assessment-Toddler version (ELSA-T)
Change in play level measured with the Structured Play Assessment (SPA)
Change in predictive gaze measured with eye-tracking
Week 12
Change in parent-child interactions

Trial Safety

Safety Progress

1 of 3

Other trials for Autism Spectrum Disorders

Trial Design

2 Treatment Groups

Jasper
1 of 2
Parent Education
1 of 2
Experimental Treatment

100 Total Participants · 2 Treatment Groups

Primary Treatment: Jasper · No Placebo Group · N/A

Jasper
Behavioral
Experimental Group · 1 Intervention: Jasper · Intervention Types: Behavioral
Parent Education
Behavioral
Experimental Group · 1 Intervention: Parent Education · Intervention Types: Behavioral
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Parent Education
2016
N/A
~620

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: assessment occurs at week 1, week 6, and week 12, with an intervention in weeks 2-11

Who is running the clinical trial?

Boston University Charles River CampusLead Sponsor
96 Previous Clinical Trials
10,404 Total Patients Enrolled
Centre National de la Recherche Scientifique, FranceOTHER
73 Previous Clinical Trials
23,844 Total Patients Enrolled
University of California, Los AngelesOTHER
1,404 Previous Clinical Trials
6,942,347 Total Patients Enrolled
University of ChicagoOTHER
917 Previous Clinical Trials
742,247 Total Patients Enrolled
Boston Medical CenterOTHER
357 Previous Clinical Trials
877,011 Total Patients Enrolled
University of Maryland, College ParkOTHER
140 Previous Clinical Trials
41,027 Total Patients Enrolled
Helen Tager-Flusberg, PhDPrincipal InvestigatorBoston University Charles River Campus
3 Previous Clinical Trials
160 Total Patients Enrolled

Eligibility Criteria

Age < 18 · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 19th, 2021

Last Reviewed: October 10th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.